


# Risking Life and Limb

A review of the quality of the care provided to adults with acute limb ischaemia

**EXTENDED  
REPORT**



**NCEPOD**

Improving the quality of healthcare

# RISKING LIFE AND LIMB

*A review of the quality of care provided to adults with acute limb ischaemia (ALI)*

A report published by the National Confidential Enquiry into Patient Outcome and Death (2025)

The National Confidential Enquiry into Patient Outcome and Death (NCEPOD) is an independent body to which a corporate commitment has been made by the medical and surgical royal colleges, associations and faculties related to its area of activity. [NCEPOD](#) is a company, limited by guarantee (3019382) and a registered charity (1075588).

The report has been compiled by:

Simon McPherson BSc MRCP FRCR EBIR, NCEPOD Clinical Co-ordinator

*Leeds Teaching Hospitals NHS Trust*

David Wood FRCP FBPhS FACCT FACMT FEAPCCT, NCEPOD Clinical Co-ordinator

*Guy's and St Thomas' NHS Foundation Trust*

Hannah Shotton PhD, Senior Clinical Researcher, NCEPOD

Leah Shahzad BSc (Hons), Researcher, NCEPOD

Marisa Mason PhD, Chief Executive, NCEPOD

The authors and trustees of NCEPOD would like to thank the NCEPOD staff for their work in collecting, importing, analysing and reviewing the data for this report: Peyman Aleboye, Donna Ellis, Heather Freeth, Rachael Gomez, Holly Hamilton, D'Marianne Koomson, Nicholas Mahoney, Eva Nwosu, Karen Protopapa, Neil Smith and Anisa Warsame.

Study proposers: Professor Arun Pherwani, Mr Sandip Nandhra, Mr Jonathan Boyle and Professor Chris Imray on behalf of the [Vascular Society](#)

This report should be cited as: The National Confidential Enquiry into Patient Outcome and Death. *'Risking Life and Limb'*. 2025. London.

*Cohort: Adults over the age of 18 years who were admitted to a vascular hub as an emergency between 1<sup>st</sup> January 2023 and 31<sup>st</sup> March 2023 for the treatment of ALI.*


The Medical and Surgical Clinical Outcome Review Programme is commissioned by the [Healthcare Quality Improvement Partnership](#) (HQIP) and funded by NHS England and the governments of Wales, Northern Ireland, and Jersey as part of the [National Clinical Audit and Patient Outcomes Programme](#).

**ISBN: 978-1-7393029-9-3**

# CONTENTS

CONTENTS.....	3
PATHWAYS OF CARE .....	4
NOTES FOR READERS.....	5
LINKS TO ADDITIONAL REPORT SECTIONS .....	5
GLOSSARY .....	5
REFERENCES.....	5
ACKNOWLEDGEMENTS USEFUL RESOURCES ON THIS TOPIC .....	5
IMPLEMENTATION SUGGESTIONS FOR THE RECOMMENDATIONS .....	5
QI TOOLS FOR THIS STUDY .....	5
INTRODUCTION FROM OUR CHAIR .....	6
INFOGRAPHIC .....	7
RECOMMENDATIONS.....	Error! Bookmark not defined.
SUGGESTIONS FOR FUTURE RESEARCH.....	8
1 METHODS.....	12
2 DATA RETURNED AND THE STUDY POPULATION.....	13
3 THE SEVERITY OF ACUTE LIMB ISCHAEMIA .....	21
4 TIME FROM SIGNS AND SYMPTOMS TO PRESENTATION .....	22
5 PRESENTATION TO PRIMARY CARE .....	25
6 PRESENTATION TO A SPOKE HOSPITAL .....	28
7 TRANSFER FROM A SPOKE HOSPITAL TO A VASCULAR HUB .....	30
8 CARE AT THE VASCULAR HUB .....	33
9 PROCEDURES UNDERTAKEN .....	38
10 DISCHARGE AND OUTCOME .....	43
11 OVERALL QUALITY OF CARE .....	48


# PATHWAYS OF CARE



Vascular networks are organised on a hub and spoke model with 58 vascular hubs and 134 spoke hospitals across England, Wales, Northern Ireland and Jersey. Vascular hubs and spoke hospitals will be used as the terminology throughout the report, but vascular hubs may also be called vascular centres or arterial centres and spoke hospitals may be called network hospitals or non-arterial centres. Spoke hospitals are those where a patient might present as there is an emergency department, but there are no 24/7 inpatient specialist vascular services.

[Click here or on the map for more details about vascular networks.](#)

The treatment of ALI first relies on the patient recognising the severity of their symptoms and then seeking medical assistance. Patients may present to primary care services, call NHS 111, call an ambulance or self-present to the emergency department at their closest hospital (which may be a vascular hub or a spoke hospital). Some may present directly to the vascular hub, knowing that it provides vascular surgical services. If an ambulance is called, it may take patients directly to a vascular hub because it is the closest hospital or by activating bypass protocols. These complex referral and transfer processes increase the risk of delays in triage, diagnosis and imaging and missed opportunities for timely initial treatment as well as transfer to the vascular hub.



The pathway of care for patients with acute limb ischaemia

# NOTES FOR READERS

## Signs of acute limb ischaemia - the '6Ps'

The possible signs of acute limb ischaemia are grouped into a phrase known as [the '6Ps'](#) and can be used to help diagnose the condition. Although it should be noted that younger people and those without all the defined six signs can still have ALI.

**Pain** - constant, usually unrelieved by over-the-counter analgesics

**Pallor** (or cyanosis or mottling)

**Paraesthesia** or reduced sensation or insensate limb

**Paralysis** or reduced power

**Perishingly cold** (poikilothermia)

**Pulselessness** - ankle pulses are always absent

## The Rutherford classification

This is a system used to categorise the severity of acute limb ischaemia once it has been diagnosed.

Grade	Category	Sensory loss	Motor deficit	Prognosis
I	Viable	None	None	No immediate threat
IIa	Marginally threatened	None or minimal (toes)	None	Salvageable if promptly treated
IIb	Immediately threatened	More than toes	Mild/moderate	Salvageable if promptly revascularised
III	Irreversible	Profound, anaesthetic	Profound, paralysis	Major tissue loss amputation. Permanent nerve damage inevitable

## LINKS TO ADDITIONAL REPORT SECTIONS

[GLOSSARY](#)

[REFERENCES](#)

[ACKNOWLEDGEMENTS](#)

[USEFUL RESOURCES ON THIS TOPIC](#)

[IMPLEMENTATION SUGGESTIONS FOR THE RECOMMENDATIONS](#)

[QI TOOLS FOR THIS STUDY](#)

# INTRODUCTION FROM OUR CHAIR

[\(BACK TO CONTENTS\)](#)

Acute limb ischaemia (ALI) is a sudden decrease in limb perfusion that threatens the viability of the limb and is a vascular emergency. It is highly treatable if diagnosed and treated promptly; delay can result in permanent disability, amputation or death. The scale of the problem is unknown as there is no consistent coding of ALI. There is a misconception that ALI is most common in older people, but this study found that the mean age was 70, with a quarter being 60 years or younger.

The most used scoring system for the severity of ALI, the Rutherford classification, has four categories (I, IIa, IIb and III). The most critical is IIb, where there is an immediate but potentially reversible threat to the viability of the limb if the target of revascularisation within six hours is not met. This requires patients to recognise the potential severity of their symptoms and seek medical attention, and healthcare professionals to make the diagnosis and treat the condition rapidly, with prompt admission or transfer to a vascular centre. Assessing patients for the '6Ps' (pain, pallor, paraesthesia, paralysis, perishingly cold and pulselessness) is essential, although not all must be present to diagnose ALI. This report found inconsistent recording of the '6Ps', with peripheral pulses being recorded in primary care in only a third of patients.

Over 90% of patients in this study had associated comorbidities (coexisting medical conditions) such as hypertension, atrial fibrillation, peripheral vascular disease and diabetes, with over 70% having multiple conditions. Almost 80% of people with ALI were current or ex-smokers. Treating these comorbidities, giving lifestyle advice and warning high-risk patients of the symptoms of ALI can help reduce the risk of ALI and ensure that people seek medical attention early.

Delays in seeking or accessing medical advice can have serious consequences for patients with ALI. It is vital that healthcare professionals triaging patients are aware of the symptoms and signs of ALI and the need for prompt treatment, ideally in a vascular centre. Vascular services are provided on a hub and spoke model, with patients presenting to spoke hospitals being transferred to vascular hubs for specialist treatment. This can add delay, making it even more important that these patients are identified quickly and prompt transfer is arranged. It is vital that supportive treatment, including anticoagulation, intravenous fluids and oxygen are started as soon as possible, and that patient records and imaging can be transferred easily.

National guidance, reporting standards, comprehensive data collection and a quality improvement framework for the treatment for ALI are recommended to improve outcomes.

I am grateful to everyone involved in developing and carrying out this study and those involved in writing the report and its recommendations.



Dr Suzy Lishman CBE, NCEPOD Chair

ACUTE LIMB ISCHAEMIA IS A SUDDEN LOSS OF BLOOD FLOW TO AN ARM OR LEG. IT IS TREATABLE IF DIAGNOSED VERY QUICKLY; DELAY CAN CAUSE PERMANENT DISABILITY, AMPUTATION OR DEATH.

## TO IMPROVE THE CARE PROVIDED TO PATIENTS WITH ACUTE LIMB ISCHAEMIA...

We reviewed the care of patients who were admitted to a vascular hub as an emergency, between 1st January 2023 and 31st March 2023 for treatment of ALI was reviewed using 330 sets of secondary care case notes, 111 primary care case notes, 293 clinician questionnaires and 105 spoke/51 vascular hub organisational questionnaires.

### Recognise acute limb ischaemia and what prompt actions to take to reduce any delay in treatment and potentially save the limb.



Delays occurred throughout the patient pathway due to a lack of recognition of the symptoms of acute limb ischaemia by both healthcare professionals and patients with the condition.

Delays to presentation were common with 144/283 (50.9%) patients presenting more than 24 hours after the onset of their symptoms.

There were missed opportunities to recognise ALI prior to admission, most commonly due to a lack of patient awareness (82/115; 71.3%) and/or recognition in primary care (24/115; 20.8%).

### Refer or transfer patients with new or worsening symptoms of acute limb ischaemia who are at high risk of losing their limb directly to a vascular hub.



Patients most likely to benefit from an intervention (Rutherford category IIb) were not always directed to a vascular hub, delaying their treatment beyond the accepted target of six hours.

The median time from arrival at the spoke hospital to arrival at the vascular hub was 8.16 hours, exceeding the time from development of symptoms to treatment target for immediately threatened limbs.

Using an ALI pathway in the vascular hub appeared to have a positive impact on care by reducing review delays.

### Organise vascular networks to provide timely access to vascular specialists skilled in treating people with acute limb ischaemia.



Networks were underused and non-vascular specialists reported not being confident to treat patients in the spoke hospitals but had no formal transfer option to the vascular hub.

There were 34/91 spoke hospitals in which medical records could be shared electronically and 56/91 in which images could be shared immediately. All other systems that were described, such as email and paper copies, risk delays or other harm.

In total, 138/330 (41.8%) patients attended a spoke hospital and were then transferred to a vascular hub.

### Develop a national guideline for the management of acute limb ischaemia.



There is no national guideline covering the care pathways between primary care, spoke hospitals and vascular hubs for patients with acute limb ischaemia.

Written guidance specific to the management of suspected ALI was available in only 56/91 spoke hospitals, and when it did exist key components were often missing.

Using an ALI pathway in the vascular hub appeared to have a positive impact on care: 3/46 (6.5%) patients experienced a delay on an ALI pathway compared to 18/165 (10.9%) not on a pathway.

### Capture focused data on acute limb ischaemia, to report on procedures and outcomes for patients with ALI.



There is no clinical code for acute limb ischaemia and no registry to record data locally, therefore the true number of patients with ALI is unknown, leading to an absence of data to promote improvement in patient outcomes.

Only 22/47 vascular hubs stated they recorded data on surgical procedures and 19/42 on interventional radiological procedures.

The use of prospectively collected data for shared learning was uncommon with most learning occurring in morbidity and mortality meetings or due to reported adverse events.



# RECOMMENDATIONS

These recommendations have been formed by a consensus exercise involving all those listed in the acknowledgements. The recommendations have been independently edited by medical editors experienced in developing recommendations for healthcare audiences to act on.

1	<p><b>Raise awareness of acute limb ischaemia, how to recognise it and what actions to take to reduce delays in the treatment pathway.</b></p> <ul style="list-style-type: none"> <li>▪ <b>Raise awareness with patients and the public about the symptoms and who to contact.</b></li> <li>▪ <b>Raise awareness with healthcare professionals in primary care, community care and all emergency departments (vascular hubs and spoke hospitals).</b></li> </ul> <p><i>Note: younger people and those without all of the defined six symptoms of ALI (Pain, Pallor, Paraesthesia, Paralysis, Perishingly cold, Pulselessness - the '6Ps') can still have ALI.</i></p>
<b>RATIONALE FOR THE RECOMMENDATION</b>	Delays occurred throughout the patient pathway due to a lack of recognition of symptoms of acute limb ischaemia by the patients and delays in recognition and diagnosis of acute limb ischaemia on behalf of the healthcare professionals. Delays can lead to amputations and should be avoided wherever possible.
<b>FOR ACTION BY</b>	<p><b>PATIENT AND PUBLIC AWARENESS</b> The Office for Health Improvement and Disparities (previously Public Health England), Public Health Wales, Public Health Agency Northern Ireland, Public Health Jersey.</p> <p><b>CLINICAL AWARENESS</b> Commissioners (including NHSE Vascular Services clinical reference group) and integrated care boards in discussion with their trusts/health boards.</p>
<b>ADDITIONAL STAKEHOLDERS</b>	Vascular Society, British Society of Interventional Radiology, NHS 111, Royal College of Surgeons of England, Royal College of Anaesthetists, Association of Surgeons of Great Britain and Ireland, Association of Anaesthetists, Royal College of General Practitioners, Royal College of Emergency Medicine, Royal College of Physicians, Royal College of Radiologists, British Society of Endovascular Therapy, Association of Ambulance Chief Executives, Joint Royal Colleges Ambulance Liaison Committee, Royal College of Nursing, Diabetes UK, Legs Matter, The Patients Association.
<b>ASSOCIATED GUIDANCE</b>	<ul style="list-style-type: none"> <li>▪ <a href="#">NHSE: PERIPHERAL ARTERIAL DISEASE, AN OVERVIEW</a></li> <li>▪ <a href="#">NHSE: COMPLICATIONS OF TYPE 2 DIABETES</a></li> <li>▪ <a href="#">PATIENT INFO: LIMB EMBOLISM AND ISCHAEMIA</a></li> <li>▪ <a href="#">ROYAL COLLEGE OF EMERGENCY MEDICINE: ACUTE LIMB ISCHAEMIA</a></li> <li>▪ <a href="#">LEGS MATTER: ACT NOW TO SAVE LIMBS AND LIVES</a></li> </ul>
<b>IMPLEMENTATION SUGGESTIONS: <a href="#">CLICK HERE</a></b>	



2	<p><b>Risk stratify and refer/transfer patients with symptoms of acute limb ischaemia and new sensory or motor impairment* directly to a vascular hub.</b></p> <p><i>*These would be patients with a <u>Rutherford IIb category</u>, affecting more than the toes See also recommendation 3</i></p>
<b>RATIONALE FOR THE RECOMMENDATION</b>	<p>Patients likely to benefit most from an intervention (<u>Rutherford category IIb</u>) were not always directed to a vascular hub, causing a delay in their treatment beyond the accepted target of six hours. Furthermore, the Rutherford classification was rarely used outside of vascular hubs.</p> <p><i>This also links with recognition in recommendation 1.</i></p>
<b>FOR ACTION BY</b>	Commissioners and integrated care boards in discussion with their trusts/health boards.
<b>ADDITIONAL STAKEHOLDERS</b>	Vascular Society, British Society of Interventional Radiology, Royal College of Surgeons of England, Royal College of Anaesthetists, Association of Surgeons of Great Britain and Ireland, Association of Anaesthetists, Royal College of General Practitioners, Royal College of Emergency Medicine, Royal College of Physicians, Royal College of Radiologists, Royal College of Nursing, Association of Ambulance Chief Executives, Joint Royal Colleges Ambulance Liaison Committee.
<b>ASSOCIATED GUIDANCE</b>	<ul style="list-style-type: none"> <li>▪ <a href="#">NICE CLINICAL KNOWLEDGE SUMMARY: ACUTE LIMB ISCHAEMIA</a></li> <li>▪ <a href="#">VASCULAR SOCIETY: PROVISION OF SERVICES FOR PEOPLE WITH VASCULAR DISEASE 2024</a></li> <li>▪ <a href="#">BRITISH SOCIETY OF INTERVENTIONAL RADIOLOGY: PROVISION OF INTERVENTIONAL RADIOLOGY SERVICES 2023</a></li> <li>▪ <a href="#">ROYAL COLLEGE OF EMERGENCY MEDICINE: ACUTE LIMB ISCHAEMIA</a></li> </ul>
<b>IMPLEMENTATION SUGGESTIONS: <a href="#">CLICK HERE</a></b>	
3	<p><b>Organise vascular networks to provide timely access to vascular specialists skilled in treating people with acute limb ischaemia.</b></p>
<b>RATIONALE FOR THE RECOMMENDATION</b>	Networks were under used and non-vascular specialists reported not being confident to treat patients in the spoke hospitals but had no formal transfer option to the vascular hub.
<b>FOR ACTION BY</b>	Commissioners and integrated care boards in discussion with their trusts/health boards.
<b>ADDITIONAL STAKEHOLDERS</b>	Royal College of Surgeons of England, Vascular Society, British Society of Interventional Radiology, Royal College of Anaesthetists, Association of Surgeons of Great Britain and Ireland, Association of Anaesthetists, Royal College of General Practitioners, Royal College of Emergency Medicine, Royal College of Physicians, Royal College of Radiologists, Association of Ambulance Chief Executives, Joint Royal Colleges Ambulance Liaison Committee.
<b>ASSOCIATED GUIDANCE</b>	<ul style="list-style-type: none"> <li>▪ <a href="#">VASCULAR SOCIETY: PROVISION OF SERVICES FOR PEOPLE WITH VASCULAR DISEASE 2021</a></li> </ul>

	<ul style="list-style-type: none"> <li>▪ <a href="#">BRITISH SOCIETY OF INTERVENTIONAL RADIOLOGY: PROVISION OF INTERVENTIONAL RADIOLOGY SERVICES 2023</a></li> </ul>
IMPLEMENTATION SUGGESTIONS: <a href="#">CLICK HERE</a>	
4	<p><b>Develop a national guideline for the management of acute limb ischaemia.</b></p>
<b>RATIONALE FOR THE RECOMMENDATION</b>	There is no national guideline covering the care pathway for patients with, or at risk of ALI from primary care to spoke hospital to vascular hubs. In addition, there is no national data collection system and no quality improvement framework. In severe cases (Rutherford IIb), patients need to be treated by specialist staff within six hours of their symptoms appearing.
<b>FOR ACTION BY</b>	The Vascular Society with the British Society of Interventional Radiology.
<b>ADDITIONAL STAKEHOLDERS</b>	Royal College of Surgeons of England, Royal College of Anaesthetists, Association of Surgeons of Great Britain and Ireland, Association of Anaesthetists, British Society for Haematology, Royal College of General Practitioners, Royal College of Emergency Medicine, Royal College of Physicians, Royal College of Radiologists, British Society of Endovascular Therapy, Association of Ambulance Chief Executives, Joint Royal Colleges Ambulance Liaison Committee.
<b>ASSOCIATED GUIDANCE</b>	<ul style="list-style-type: none"> <li>▪ <a href="#">NICE CLINICAL KNOWLEDGE SUMMARY: ACUTE LIMB ISCHAEMIA</a></li> <li>▪ <a href="#">VASCULAR SOCIETY: PROVISION OF SERVICES FOR PEOPLE WITH VASCULAR DISEASE 2024</a></li> <li>▪ <a href="#">BRITISH SOCIETY OF INTERVENTIONAL RADIOLOGY: PROVISION OF INTERVENTIONAL RADIOLOGY SERVICES 2023</a></li> </ul>
IMPLEMENTATION SUGGESTIONS: <a href="#">CLICK HERE</a>	
5	<p><b>Support the national vascular registry to capture focused data on acute limb ischaemia, and to report on procedures and outcomes for patients with ALI*</b></p> <p><i>*ICD-11 will be mandated in the UK in the next five years and has codes for upper and lower ALI that will allow data comparisons with the national vascular registry data and national patient episode data, unlike ICD-10 where ALI is coded with chronic limb-threatening ischaemia.</i></p>
<b>RATIONALE FOR THE RECOMMENDATION</b>	There is no UK data collection (registry) on acute limb ischaemia. This needs to be in place to monitor and improve outcomes and allow benchmarking for quality improvement.
<b>FOR ACTION BY</b>	Funders and commissioners of the national vascular registry, working with the Royal College of Surgeons of England and partners as the current contract holder for the registry.
<b>ADDITIONAL STAKEHOLDERS</b>	Vascular Society, British Society of Interventional Radiology, NHSE Vascular Services Clinical Reference Group, Vascular Anaesthetic Society of Great Britain and Ireland
<b>ASSOCIATED GUIDANCE</b>	<ul style="list-style-type: none"> <li>▪ <a href="#">EUROPEAN SOCIETY FOR VASCULAR SURGERY (ESVS) 2020 CLINICAL PRACTICE GUIDELINES ON THE MANAGEMENT OF ACUTE LIMB ISCHAEMIA</a></li> </ul>
IMPLEMENTATION SUGGESTIONS: <a href="#">CLICK HERE</a>	

## SUGGESTIONS FOR FUTURE RESEARCH

- Anticoagulation options for patients not requiring immediate/early revascularisation
- Assessment of the impact of ethnicity, body mass index (BMI), alcohol consumption, and cognitive baseline on outcomes (not collected in the National Vascular Registry)
- Variation in outcomes by socioeconomic status/postcode
- The impact of vaping and electronic tobacco products on cardiovascular disease in general
- The role of endovascular embolectomy/thrombectomy systems to establish their role and cost effectiveness
- Improved risk stratification system for patients with acute limb ischaemia
- Collection of acute limb ischaemia patient reported outcomes.

### ONGOING RESEARCH TO NOTE

- The [ESTAbLIsh Trial](#), a randomised controlled trial comparing open surgical to endovascular treatment for people with ALI, will run from 4/5/26 for two years
- Medical management after acute limb ischaemia using [Cardiovascular Outcomes for People Using Anticoagulation Strategies \(the COMPASS Trial\)](#) vs subgroup focused.

# 1 METHODS

## DETAILED FINDINGS ABOUT THE METHODS ARE AVAILABLE HERE

[\(BACK TO CONTENTS\)](#)

### **Study advisory group**

A multidisciplinary group of clinicians was convened to steer the study from design to completion, define the objectives of the study and advise on the key questions. The group comprised lay and patient representatives and healthcare professionals in vascular surgery, interventional radiology, vascular nursing, general nursing, anaesthesia, diabetes care, emergency medicine, haematology and general practice.

### **Study aims and objectives**

The objectives of the study were to explore the current care pathways for patients with acute limb ischaemia (ALI) to identify the remediable clinical and organisational factors that could improve ALI care.

### **Study population and case ascertainment**

#### **Inclusion criteria**

Adults over the age of 18 years who were admitted to a vascular hub as an emergency, between 1<sup>st</sup> January 2023 and 31<sup>st</sup> March 2023 for treatment of ALI.

#### **Exclusion criteria**

Patients who received only anticoagulation or palliative care at a spoke hospital.

#### **Identification of a sample population**

The incidence of ALI is unknown as there is no ICD-10 code for ALI. The identification of ALI was made more challenging by its many modes of presentation and breadth of treatment options, which are often used to treat chronic limb-threatening ischaemia. A local study contact (vascular surgeon or vascular radiologist) had to screen patient notes to identify those with acute limb ischaemia from those with chronic limb-threatening ischaemia. Patients were randomly selected from this sample.

#### **Data collection**

- **A clinician questionnaire** was sent to the named vascular surgeon.
- **A primary care questionnaire** was sent to the listed GP surgery for each included patient.
- **A vascular hub or spoke hospital organisational questionnaire** was used to collect data on the organisational structures in place to deliver the service to patients who have ALI.
- **Copies of the case notes** were requested for the included admission for peer review by a multidisciplinary group of case reviewers.
- **Surveys** were completed anonymously by patients and healthcare professionals.

#### **Data analysis rules**

- Small numbers have been suppressed if they risk identifying an individual (usually <3-5)
- Any percentage under 1% has been presented in the report as <1%
- Percentages were not calculated if the denominator was less than 100 so as not to inflate the findings, unless to compare groups within the same analysis
- There will be variation in the denominator for different data sources and for each individual question as it is based on the number of answers given.

## 2 DATA RETURNED AND THE STUDY POPULATION

### Age

It is widely believed that acute limb ischaemia (ALI) predominantly occurs in older people. The European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia states that the large majority of ALI occurs in people over 80 years of age,<sup>[1,2]</sup> while the NICE clinical knowledge summary advises that ALI usually affects people aged over 60 years.<sup>[3]</sup>

The mean age for patients included in this study was 71 years. The effect of selection bias due to the exclusion of patients who received palliative care in spoke hospitals was thought to be minimal by the study advisory group.

In total, 70/290 (24.1%) patients were 60 years or younger and 92/290 (31.7%) were of working age (65 or younger) (F2.1). These data highlight that age should not be a factor to exclude ALI in any adult with an acutely painful limb and highlights the need for a national registry for ALI to better understand the population and their needs

There were 193/293 (65.9%) men in the study sample and 100/293 (34.1%) women.




Figure 2.1 Age and sex of the study population;  $n=293$ ,  $mean=71$ ,  $median=72$ ,  $mode=86$   
Clinician questionnaire data

### Ethnicity

There were 260/268 (81.7%) patients in the study sample who were White, which was higher than the national population of 81.7%.<sup>[4]</sup> However, this is consistent with the population in a similar vascular review of lower limb bypass grafts<sup>[5]</sup> and was confirmed by the healthcare professionals involved in the study, so it is not believed that our dataset has under recorded the incidence of ALI in Black and ethnic minority patients (T2.1). However, it is recognised that training for healthcare

professionals may be required to help diagnose ALI in patients with darker skin, where pallor, one of the '6Ps' can be harder to identify.<sup>[6-8]</sup>

Table 2.1 Ethnicity of the study population	Number of patients	%	National Census Data 2021
White British/White - other	260	97.0	81.7
Asian/Asian British (Indian, Pakistani, Bangladeshi, Chinese, other Asian)	4	1.5	9.3
Black/African/Caribbean/Black British	2	<1	4.0
Other ethnic group	2	<1	2.1
Mixed or multiple ethnic groups	0	0	2.9
<b>Subtotal</b>	<b>268</b>		
Unknown	25		
<b>Total</b>	<b>293</b>		

*Clinician questionnaire data*

Ethnicity is not currently recorded in registries such as the National Vascular Registry nor in hospital episode statistics recorded in secondary care but is available from primary care datasets. Recording of national comprehensive data including ethnicity or linkage to primary care datasets (at patient level - NHS number) would allow future assessment of any biases in study population.<sup>[4]</sup> Furthermore, as it is well documented that Black and ethnic minority groups can experience lack of access to healthcare, delayed interventions, worse outcomes, and racial discrimination in all areas of healthcare, recording of ethnicity in national datasets would ensure that all patients with ALI, irrespective of ethnicity or socio-economic group are identified and treated promptly.<sup>[5,9-12]</sup>

## Comorbidities

Comorbidities (coexisting medical conditions) associated with an increased risk of ALI, or which might contribute to delayed presentation, were present in 257/290 (88.6%) patients, with 212/290 (73.1%) patients having more than one (F2.2).

Almost a quarter of patients presenting with ALI had type 2 diabetes mellitus, while type 1 was much less associated. Excessive alcohol use, illicit drug use, mental health issues or dementia are likely to affect compliance with medication or delay presentation to healthcare providers (F2.2). One or more of these factors was identified in 46/293 (15.7%) patients.

A total of 40/293 (13.7%) patients had cancer. Arterial thrombosis, often linked to cancer or its treatment, is associated with poor limb salvage rates and a survival of less than six months for most patients.<sup>[13]</sup>




Figure 2.2 Comorbidities in the study population. *Answers may be multiple; n=293*  
*Clinician questionnaire data*

## Medications

In total, 211/293 (72.0%) patients were taking one or more than one medication, including 24.9% (73/293) who were taking anticoagulants (T2.2).

Table 2.2 Medications on admission	Number of patients	%
Anti-hypertensives	128	45.4
Lipid-lowering drugs	117	41.5
Single anti-platelet	90	31.9
None	56	19.9
Direct oral anticoagulants (DOAC)	44	15.6
Dual anti-platelet	16	5.7
Warfarin	16	5.7
Other anticoagulants	14	5.0
Hormone treatment	2	<1%

*Answers may be multiple; n=282, unknown in 11*  
*Clinician questionnaire data*



More than a third (33/81; 40.7%) of patients with pre-existing atrial fibrillation (AF) were not receiving anticoagulants, This suggests an area where care could be improved while recognising that some patients may have not been offered an anticoagulant after a risk-benefit assessment, declined it or, if at high risk of anticoagulation complications, been offered antiplatelet treatment. There were 10/81 (12.3%) patients with AF who were receiving a single antiplatelet agent. A single antiplatelet was prescribed in addition to anticoagulation in 5/81 (6.2%) patients with AF.

## Smoking status

Smoking rates in the UK have fallen from 46% in 1974 to 12.9% in 2022. In 2023, 11.9% of adults aged 18 years or over (6.0 million people) were current smokers, according to the Office for National Statistics (ONS).<sup>[14]</sup> In this study 117/266 (44.0%) patients were current smokers and 94/265 (35.5%) were ex-smokers, underscoring the importance of smoking as a risk factor for ALI (T2.3).

Table 2.3 Smoking status of the study population	Number of patients	%
Current smoker	117	44.2
Ex-smoker	94	35.5
Never smoked	54	20.4
<b>Subtotal</b>	<b>265</b>	
Unknown/vaper	28	
<b>Total</b>	<b>293</b>	

*Clinician questionnaire data*

This study did not actively collect data on heated tobacco products and e-cigarettes (vapes). Use was noted only when incidentally recorded. E-cigarettes (vapes) are advocated as an alternative to smoking, including the ‘Swap to Stop’ campaign. The Office for National Statistics estimates that 5.9% of adults in the UK used an e-cigarette daily in 2023, up from 5.2% in 2022.<sup>[15]</sup> E-cigarettes are regulated under the Tobacco and Related Products Regulations 2016, and are not subject to any of the safety studies required for medical devices and drugs before they can be used.

The Medicines and Healthcare products Regulatory Agency (MHRA) recommends recording e-cigarette use in medical records similar to smoking, to facilitate future studies on their long-term effects. However, it recommends recording details of the brand(s), active components and strength(s), which might not be practical to collect.<sup>[16]</sup> While the long-term effects of vaping are not known, research has identified negative impacts on the cardiovascular system.<sup>[17,18]</sup> Specific to peripheral arterial disease (PAD) and ALI, there is evidence of short-term harmful effects on normal peripheral vessels similar to those caused by smoking, even in products containing no nicotine.<sup>[19]</sup> The recording of e-cigarette use is not yet embedded in medical training and while there is an increasing recognition of the harmful effects, understanding remains limited.

## Social situation

Prior to the hospital admission with ALI, 261/282 (92.6%) patients were living in their own home (T2.4). Where the data were available, the majority of patients were managing without additional social support or care (189/261; 72.4%).

Table 2.4 Usual place of residence	Number of patients	%
Own home	261	92.6
Residential home	12	4.3
Nursing home	5	1.8
Other/homeless	4	1.4
<b>Subtotal</b>	<b>282</b>	
Unknown	11	
<b>Total</b>	<b>293</b>	

*Clinician questionnaire data*

## Frailty

A Rockwood Clinical Frailty Score at admission was estimated by the reviewers where one was not recorded in the notes (F2.3). The Rockwood Clinical Frailty Scale was originally validated in the assessment of frailty in those aged 65 years or older.<sup>[20]</sup>

It has been routinely used in recent NCEPOD reports and has been shown to be a better predictor of outcomes than age for all adults.<sup>[21]</sup> Frailty has also been recognised as having a greater impact than age across older age ranges.<sup>[22]</sup>

Reflecting on their place of residence and social support needs, 162/330 (49.1%) patients were fit, well or managing well prior to their admission (F2.3). While severe frailty was recorded in 40/330 (12.1%), it should be noted that this might have been higher if patients who received palliative care in spoke hospitals had been included.




Figure 2.3 Estimated Rockwood frailty score prior to admission;  $n=330$

*Case review data*

## Communication difficulties

In total, 34/305 (11.1%) patients had communication difficulties comprising language (10), hearing (8), learning disability/difficulties (5) and post-stroke impairments (4), which may make it harder to communicate symptoms of ALI quickly (T2.5).

Table 2.5 The patient had communication difficulties	Number of patients
Language	10
Hearing difficulties	8
Dementia	5
Learning difficulties/disability	5
Dysphasia/cognitive impairment post-stroke	4

Answers may be multiple; n=34

Case review data

## Presentation of symptoms

The majority of patients in the study had a lower limb affected with ALI (303/330; 91.8%) (T2.6). Most patients had only one limb affected, but a small number had more than one limb affected (F2.4). The involvement of multiple limbs suggests a proximal embolic source. All the patients who had atrial fibrillation and multiple limbs affected had been prescribed an anticoagulant prior to their admission. However, the patients' compliance with, and the effectiveness of their anticoagulant prescription, was unknown.

Table 2.6 The presenting limb	Number of patients	%
Lower limb	303	91.8
Upper limb	28	8.5

Answers may be multiple; n=330

Case review data




Figure 2.4 Presenting limb; n=330

Case review data

An arterial aneurysm is a recognised source of material that can cause a blockage in a limb. In this study 27/290 (9.3%) patients were known to have an aneurysm in the affected limb or at an earlier point in the blood supply to the limb.

This admission was the first episode of ALI for 241/293 (82.3%) patients, but 25/293 (8.5%) had experienced an episode of ALI in the previous ten years (history of ALI was unknown for 27 patients). There were 60/293 (20.5%) patients who had undergone previous surgical or endovascular revascularisation procedures for ALI or peripheral artery disease (PAD) and 11/293 (3.75%) patients who had undergone a previous amputation. Monitoring ALI procedures and outcomes at a national level would provide a benchmark for assessing readmissions/recurrence of disease.

The majority of patients had no ischaemic symptoms in the presenting limb before this presentation (178/293; 60.8%). Minor chronic PAD may not have any symptoms. When symptomatic chronic PAD causes intermittent claudication or more severely, chronic limb-threatening ischaemia (CLTI) with one or more of rest pain, tissue loss, gangrene or ulceration. The clinicians in the vascular hub identified 109/293 (37.2%) patients with symptoms of chronic PAD in the presenting limb (T2.7).

Table 2.7 Prior condition of the presenting limb	Number of patients	%
Asymptomatic	178	60.8
Intermittent claudication	63	21.5
Rest pain	46	15.7
Tissue loss/gangrene/ulceration	11	3.8
Nothing recorded	5	1.7
Discolouration	3	1.0
Other	3	1.0

*Answers may be multiple; n=293*

*Clinician questionnaire data*

The reviewers identified a higher prevalence of CLTI prior to the admission, identifying 111/330 (33.6%) patients as having acute-on-chronic limb ischaemia.

Most patients with CLTI will have sought medical advice for their symptoms. Intermittent claudication is commonly managed conservatively, at least initially, in the UK. In other healthcare systems intervention is common. It is unknown how many patients with intermittent claudication had sought medical advice, but it is likely many will have been seen in primary care, and some will have seen a vascular surgeon. Patients with symptomatic PAD will have widespread atherosclerosis and are at high risk of cardiovascular events, yet they are often undertreated with medical therapies.<sup>[23,24]</sup>

Lipid-lowering drugs were prescribed to 117/293 (39.9%) patients and to 49/109 (45.0%) patients with symptoms of chronic PAD. Whether these low rates were due to lack of assessment and/or prescription or patient decision or intolerance could not be determined.

In this study, only 11 patients in total and six patients with symptomatic PAD were taking a direct oral anticoagulant (DOAC) and antiplatelet agent.<sup>[25]</sup> Irrespective of whether intervention is a

consideration, patients with chronic PAD should be offered appropriate medical management, in addition to promoting healthy behaviours, to reduce life and limb-threatening events. This study suggests that such simple preventative strategies are not well embedded in the current management of PAD.

Seeing a patient with chronic PAD in clinic offers valuable educational opportunities. These include provision of information on the symptoms of ALI and who to contact, and empowering patients to present rapidly to the vascular hub if they develop loss of sensation and or movement in association with acute limb pain.

The reviewers considered that there was room for improvement in the care of 21/111 (18.9%) patients with CLTI. The reasons (answers may be multiple) included eight who had previously seen a GP with ALI, nine who had delayed treatment of their deteriorating chronic ischaemia and five with lifestyle modifiable factors which were not addressed.

### 3 THE SEVERITY OF ACUTE LIMB ISCHAEMIA

[\(BACK TO CONTENTS\)](#)

The first-line treatment for acute limb ischaemia, unless the patient needs palliative care only, is anticoagulation, intravenous (IV) fluids and supplemental oxygen.<sup>[26]</sup> Analgesia is also essential, with involvement of the acute pain team as needed.<sup>[27]</sup>

Once a diagnosis has been made, the urgency of treatment is determined by whether there is newly altered sensation and/or movement in an acutely painful limb. This simple assessment can be carried out by all healthcare professionals, including nurses and allied health professionals.

To understand the urgency and quantify the severity of a patient’s condition to facilitate communication between healthcare professionals the Rutherford classification is used (T3.1).<sup>[27,28]</sup>

Grade	Category	Sensory loss	Motor deficit	Prognosis
I	Viable	None	None	No immediate threat
IIa	Marginally threatened	None or minimal (toes)	None	Salvageable if promptly treated
IIb	Immediately threatened	More than toes	Mild/moderate	Salvageable if promptly revascularised
III	Irreversible	Profound, anaesthetic	Profound, paralysis	Major tissue loss amputation. Permanent nerve damage inevitable

The ESVS 2020 ALI guideline made some minor modifications to the original Rutherford classification.<sup>[28]</sup> The full classification includes the use of handheld arterial and venous Doppler, an assessment tool generally only used by vascular specialists.

Distinguishing between the classifications of Rutherford IIa and IIb, and between IIb and III, can sometimes be challenging.<sup>[1]</sup> Not all patients with ALI require revascularisation or amputation. Some will be appropriately treated with anticoagulation alone (primarily those with ALI, Rutherford I).

The Rutherford category may deteriorate, particularly with delays to treatment, as the lack of blood supply causes tissue and nerve damage. Without treatment Rutherford IIa ALI will usually progress to IIb and then III. Patients with ALI categorised as Rutherford IIb the accepted plan is that patients require revascularisation as soon as possible and ideally within six hours for fully functional limb salvage.

Compartment syndrome where swollen muscles compress the arterial supply and venous drainage is related to the severity and duration of ALI.<sup>[29]</sup> It may be aggravated by revascularisation and increases the risks of amputation, muscle necrosis and nerve damage. Performing a fasciotomy can relieve the compartment pressure<sup>[30]</sup> but should be performed within two hours;<sup>[1]</sup> waiting longer than six hours is not acceptable practice<sup>[28]</sup> as fasciotomies are not without risk and complications can include infection, and the need for skin grafts.<sup>[31]</sup>

# 4 TIME FROM SIGNS AND SYMPTOMS TO PRESENTATION

## Initial symptoms

Determining the time from the onset of acute limb ischaemia (ALI) symptoms to the first presentation to any healthcare professional is challenging. It relies on the patient's recollection of events, the level of detail recorded in the medical history, and the combination of medical records that may be on more than one healthcare system. For the 283 patients where the reviewers were able to make an assessment, the median time from symptoms to presentation was 1.1 days (F4.1).




Figure 4.1 Time from onset of symptoms to first presentation to healthcare;  $n=283$

Case review data

There were only 65/283 (22.9%) patients who presented within six hours of their symptoms starting. A further 38/283 (13.4%) patients presented between six and 12 hours and 36/283 (12.7%) between 12 and 24 hours (F4.2). Delays to presentation were common, with 144/283 (50.9%) patients presenting more than 24 hours after the onset of their symptoms. National data on delay to presentation would help target education and patient awareness campaigns.




Figure 4.2 Time from onset of symptoms to first presentation to healthcare in hours;  $n=283$

Case review data



When time to presentation was assessed against the Rutherford classification (in the vascular hub), 20/62 (32.2%) patients with a Rutherford IIb category first presented to healthcare within six hours and 43/62 (69.3%) presented within 24 hours (F4.3).




Figure 4.3 Time from onset of symptoms to first presentation to healthcare split by Rutherford category  
Case review data

The group of patients with a Rutherford IIa category presented later than those with Rutherford IIb. While it is unknown if the patient’s limbs would have been salvageable had they presented earlier, improvements in limb salvage can only occur if there are opportunities to assess and treat earlier. This underscores the need for greater awareness and consideration of the symptoms of ALI.

NHS 111, whose advice algorithm directs patients to attend their local emergency department, was rarely used (or rarely recorded in the notes) (12/325; 3.7%) (T4.1) but when it was, the median time from onset of symptoms to contact with NHS 111 was 4.8 hours (F4.4).

Table 4.1 Healthcare provider that the patient first presented to	Number of patients	%
Self-presented to a vascular hub emergency department	83	25.5
Self-presented to a spoke hospital emergency department	79	24.3
999 call	69	21.2
Primary care	68	20.9
Presented at an outpatient clinic	14	4.3
NHS 111	12	3.7
<b>Subtotal</b>	<b>325</b>	
Unknown	5	
<b>Total</b>	<b>330</b>	

Case review data

Patients with ALI who self-presented to a spoke emergency department also had shorter median times to presentation (23.5 hours) than those who presented to a vascular hub emergency department (1.3 days) or primary care (1.9 days) (F4.4). All the groups varied widely with ranges from

less than six hours to one month. These differences may reflect the symptoms the patient was experiencing or the relative difficulties in accessing primary healthcare advice, while others may have delayed seeking medical advice due to a lack of awareness of the seriousness of their symptoms or other patient factors that affected their healthcare.

*“I was on phone for ages to get GP appointment, then had to wait for my son to take me. I was in a lot of pain. Lots of waiting around and sent from one hospital to another. I didn’t really know what was going on.”* Quote from the patient survey




Figure 4.4 Time from onset of symptoms to first presentation to healthcare split by where the patient first presented

*Case review data*

In 60/330 (18.2%) sets of notes reviewers thought that patient factors delayed their presentation. The commonest reason was lack of patient awareness (25/60) with ‘chaotic lifestyle’, including not engaging with healthcare in 16/60 and vulnerability/mental health problems in 9/60. Four patients were also noted to have communication difficulties e.g. English as a second language. When patient factors delayed presentation the reviewers considered the outcome was more than likely affected for 11/60 patients.

There were missed opportunities to recognise ALI prior to admission, most commonly due to a lack of patient awareness (82/115; 71.3%) and/or recognition in primary care (24/115; 20.8%). The reviewers noted that there was also a missed opportunity to recognise ALI by NHS 111. These findings support a public and pre-hospital services awareness campaign, similar to that for stroke.

## 5 PRESENTATION TO PRIMARY CARE

Of the 249 patients who had a procedure (revascularisation and/or amputation), the majority presented to a hospital, contacted their GP or called 999 (188/249; 75.5%). Those who presented directly to a hospital had a median time to procedure of 1.2 days compared with those patients who went to primary care first. Their median time to procedure was longer at 2.3 days (F5.1). There were 16/58 vascular networks where it was reported that a referral service/pathway was integrated with primary care.




Figure 5.1 Time from first presentation to healthcare to time of first procedure

Case review data

The NICE clinical knowledge summary on peripheral arterial disease (PAD) is available to all healthcare professionals.<sup>[3]</sup> In the section ‘What are the clinical features of ALI’, it documents the ‘6Ps’ of ALI, which every medical student is taught:

**Pain** constant, usually unrelieved by over-the-counter analgesics

**Pallor** (or cyanosis or mottling)

**Paraesthesia** or reduced sensation or insensate limb

**Paralysis** or reduced power

**Perishingly cold** (poikilothermia)

**Pulselessness** ankle pulses are absent

What is less well taught or remembered, is that not all of the ‘6Ps’ need to be present to make a diagnosis of ALI and that it is rare to have all of them even in cases of severe ischaemia.<sup>[3,27]</sup> Detailed local written guidance to assist in the recognition and initial management of ALI was available in 36/111 (32.4%) primary care organisations. It was noteworthy that in 41/111 (36.9%) this was unknown. There are additional NICE resources available to primary care, such as the ALI template produced by Arens/Emis (medical software used in primary care).

Details of what the local guideline covered were not sought but GPs were asked “*What would you expect to happen in your practice if a patient presented with ALI?*”

There were 79/111 (71.2%) primary care organisations where it was expected that the ‘6Ps’ would be recorded, yet they were recorded in only 21/48 (43.8%) patients. Other aspects of clinical assessment were inconsistently performed or recorded, e.g. examining the limb in 30 patients and documenting a pain score in fewer than five patients. A Rutherford category was not recorded for any patients in primary care. Most GPs predicted that the patient would be referred to the nearest emergency department or vascular hub, but this occurred in 27/48 patients and 12/48 patients respectively, demonstrating some disconnection between expected standards and the reality of clinical practice (F5.2).




Figure 5.2 Primary care: assessment, diagnosis and actions. Actions that this GP practice stated they performed for patients with ALL; n=111, patients with ALL seen at this GP practice; n=48  
 Primary care questionnaire data

Pain was the most frequently recorded of the ‘6Ps’ (42/48) (T5.1). It is important to record the absence as well as the presence of the ‘6Ps’ as not all will be present in every patient. Review of the case notes did not allow differentiation between information not collected and symptoms that were not present.

Table 5.1 Signs of ALL at presentation to primary care	Number of patients	%
Pain	42	87.5
Pallor	17	35.4
Pulseless limb	15	31.3
Perishingly cold (poikilothermia)	15	31.3
Paraesthesia	10	20.8
Swollen limb	6	12.5
Paralysis	3	6.3
Unknown	2	4.2

Answers may be multiple; n=48  
 Primary care questionnaire

Acute limb ischaemia was diagnosed or suspected in 21/48 patients attending primary care. In 27/48 ALI was not diagnosed, but other vasculitis, cellulitis, or deep vein thrombosis were.

Patients with these conditions often present with painful, swollen limbs. Limb swelling is not usually described as a feature of ALI; however, leg swelling was present in 6/48 patients in our study including two who had no other symptoms.

Making a correct diagnosis of ALI in primary care is not essential, provided it is recognised that the patient requires urgent assessment. Most patients (41/45) had an emergency transfer to hospital, including two thirds (28/45) who were sent directly to the vascular hub from primary care. The need to expedite care was not identified in 4/45 patients, who were advised to return home and go to the emergency department if their symptoms deteriorated (T5.2).

<b>Table 5.2 Directions given following attendance in primary care</b>	<b>Number of patients</b>
Emergency transfer to a vascular hub	28
Emergency transfer to the nearest emergency department	13
Advice to return to place of residence and to attend the nearest emergency department if symptoms got worse	4
<b>Subtotal</b>	<b>45</b>
Unknown	3
<b>Total</b>	<b>48</b>

*Primary care questionnaire*

## 6 PRESENTATION TO A SPOKE HOSPITAL

[\(BACK TO CONTENTS\)](#)

In total, 138/330 (41.8%) patients had attended a spoke hospital before being transferred to a vascular hub. There were 72/138 (52.2%) patients taken by ambulance and ALI was mentioned on the patient report form (PRF), where it was available, for 29 patients. For 22 patients ALI was not mentioned on the PRF. This suggests that ambulance bypass protocols for ALI are not universal or that existing protocols are not being followed. More importantly, it highlights a simple opportunity to reduce delays in the ALI patient pathway. Case reviewers believed that 31/72 patients would have benefited from being taken directly to a vascular hub.

In the organisational questionnaire, 21/55 vascular hubs reported that an ambulance bypass protocol was in use, but only one ambulance trust that responded stated a bypass protocol was used. However, it should be noted that clinical assessment and discussion with the patient should be considered to prevent transfers that offer no clinical benefit.

The clinicians at the hospital also identified delays in the patient presenting to their local hospital in 31 instances, with patients delaying seeking help being the most common reason (T6.1).

Table 6.1 Reasons for the delay in the patient presenting to a hospital	Number of patients
Patient delayed seeking help	22
Patient sought help from primary/ambulatory care was misdiagnosed and discharged home	5
Patient presented to primary care - referred to spoke hospital	5

*Answers may be multiple; n=31*

*Clinician questionnaire data*

In the view of the reviewers there was a delay in the triage/streaming process for 18/138 (13.0%) patients and a delay in the initial assessment in 21/138 (15.2%). Misdiagnosis (6/19) was the most common reason for delay. This highlights the need for further information for patients as well as for the healthcare professionals involved in assessment/triage.

A brief education document describing ALI assessment, management and differential diagnoses was made available to all healthcare professionals in 2022 by the Royal College of Emergency Medicine.<sup>[27]</sup>

In the spoke hospital, 113/138 (81.9%) patients had all necessary assessments completed. Where omissions were identified, they were in the recording of limb power and/or pulses (six) and imaging/Doppler ultrasound in nine patients.

Delays were reported in the examination/investigations in 17/138 (12.3%) patients. Imaging should not delay a transfer but if it can be performed quickly without causing a delay, it can be beneficial for planning treatment in advance. Although, this applies only if imaging can be shared electronically; otherwise, it may pose an unnecessary risk of repeated imaging at the vascular hub.

## Rutherford classification

A Rutherford category was recorded in the notes of only 6/138 (4.3%) patients, indicating either a lack of awareness of it or a lack of confidence in using it by non-vascular specialists. According to the clinician survey, 31/32 emergency medicine/acute care physicians recorded the '6Ps' but only 1/32 routinely recorded a Rutherford category, despite 31/32 receiving postgraduate or workplace training in the assessment of ALI. When a Rutherford category was not recorded, the reviewers estimated the Rutherford category based on the patient history and examination in the hospital notes (where they were able).

The Rutherford category for the patients attending the spoke hospital indicated that 30/106 (28.3%) required revascularisation within six hours of their development of sensory-motor symptoms, while 8/106 (7.5%) probably required a primary amputation (Table 6.2). In total, at least 38/106 (35.8%) patients were in a hospital where the treatment they required could not be provided, suggesting that many vascular networks are missing the organisational opportunities to improve the care of ALI.

Table 6.2 Rutherford category in the spoke hospital (combination of recorded in notes and estimated by reviewers)	Number of patients	%
Rutherford I	13	12.3
Rutherford IIa	55	51.9
Rutherford IIb	30	28.3
Rutherford III	8	7.5
<b>Subtotal</b>	<b>106</b>	
Unable to calculate	32	
<b>Total</b>	<b>138</b>	

*Case review data*

A total of 36/138 (26.1%) patients were admitted to a medical ward in the spoke hospital before they were transferred to the vascular hub, including 3/36 patients initially misdiagnosed as having a deep vein thrombosis. Admission to a ward did not appear to be influenced by those with viable limbs or inevitable amputations.

Patients with threatened but salvageable limbs accounted for 25/36 ward admissions. Emergency transfer to a vascular hub was indicated in these patients. The decision to admit a patient or keep them in the emergency department pending transfer should always be clinically driven. It is likely that transfer from a ward would be slower than from the emergency department. Patients with ALI who require care in a vascular hub should receive that care as quickly as possible and not be admitted to a ward.

A record of the discussion with the vascular hub was evident in 118/138 (85.5%) cases reviewed, while 9/23 (39.1%) respondents in the clinician survey identified difficulties contacting the vascular surgical team as a barrier to care.



# 7 TRANSFER FROM A SPOKE HOSPITAL TO A VASCULAR HUB

[\(BACK TO CONTENTS\)](#)

In total, 7/78 spoke hospitals described a network where they referred to two or more vascular hubs. A more complicated picture emerged with the number of spoke hospitals from which the vascular hub received referrals. This ranged from zero to 22, with a mean of 3.54 and mode of two. The total number of spoke hospitals this was based on was 170, suggesting that there are 36 spoke hospitals referring to more than one vascular hub. Since the first stage of defining a vascular network is determining the hospitals it includes, this variation suggests some confusion in network boundaries.

All the patients in this study were admitted to a vascular hub. In 16/50 vascular hubs, at least one spoke hospital within the network was more than an hour away by blue light ambulance in working hours. The median time from arrival at the spoke hospital to arrival at the vascular hub was 8.16 hours, exceeding the recommended target for treatment of immediately threatened limbs (Rutherford IIb) from relevant sensory-motor symptom onset.

For 34/138 (24.6%) patients the reviewers reported that the time spent at the spoke hospital was too long. Waiting for an ambulance was the most common reason for the delay (11/34) (T7.1).

Table 7.1 Details of the delay in the transfer to a vascular hub	Number of patients
Waiting for an ambulance for the transfer	11
Decision-making in the spoke hospital	9
Referral/acceptance at the vascular hub	7
Distance needed to travel to the vascular hub	2
Unclear	4

*Answers may be multiple; n=34*

*Case review data*

There were 13/81 (16.0%) patients who had a delay of greater than 24 hours (F7.1). The nine patients who had a deterioration in their Rutherford category in the spoke hospital had a mean transfer time of ten hours (range 3.9 to 19.4 hours). Reviewers stated that eight patients would have benefited from being admitted directly to the vascular hub.

All responding ambulance trusts stated that a Category 2\* transfer would be booked if the clinician booking the transfer considered that there was a risk to a limb. It appears that the existing vascular network and ambulance pathways and protocols are not fulfilling the needs of patient networks for those with ALI. \*Category 2 is a target response time average of 18 minutes, with 90% of calls being responded to within 40 minutes. For 2023/24 and 2025/26, the national target is an average of 30 minutes.




Figure 7.1 Time from presentation to spoke hospital to arrival in vascular hub;  $n=81$   
Case review data

A well-organised vascular network should be able to reduce the issues that have been identified with presentations to spoke hospitals. Written guidance specific to the management of suspected ALI was available in only 56/91 spoke hospitals (77.2%), and where it existed key components were often missing. In 18/56 there was no single referral contact point at the vascular hub and 16/56 had no description covering the referral. The urgency of the ambulance transfer was not documented in 31/56 and expected timeframes were only documented in nine. The Rutherford category was included in only 8/56 spoke hospital guidelines which may explain why it was so infrequently used.

Table 7.2 Details of ALI guidance in spoke hospitals	Number of hospitals
A protocol covering the process of referring the patient to the vascular hub	40
Referrals to the vascular hub via a defined vascular surgical single point of contact	38
A protocol for the assessment and recognition of ALI	31
Category/urgency of ambulance transfer	25
Preferred imaging modalities for patients with symptoms of ALI	24
A transfer protocol covering the patient transfer to the vascular hub	24
A protocol covering medical treatment of patients who are not transferred	13
Recommended timeframes for the completion of required steps on the pathway	9
A protocol covering the discharge of repatriated patients ensuring all necessary onward referrals and follow-up appointments are made	9
Inclusion of a 'Rutherford' or other severity scale	8
A protocol/standard operating procedure covering the process of repatriating the patient to the spoke hospital following treatment at the vascular hub	8

Answers may be multiple;  $n=56$

Spoke hospital organisational data

When patients are transferred between hospitals sharing their medical records and imaging is essential for safe and expeditious treatment. There were 34/91 spoke hospitals in which medical

records could be shared electronically and 56/91 in which images could be shared immediately (T7.3). All other systems that were described, such as email and paper copies, risk delays or other harm.

Table 7.3 Record sharing in vascular networks for patients treated for AII	Number of spoke hospitals
The spoke hospital and the vascular hub are on the same electronic imaging archiving system, which allows immediate sharing of image reporting	56
The patient case notes sent to the vascular hub are primarily on paper and travel with the patient	42
The spoke hospital and the vascular hub are on the same electronic patient record system, allowing immediate sharing of written case notes	34
Patient case notes are normally emailed to the vascular hub	6

*Answers may be multiple, n=91*

*Spoke hospital organisational data*

## 8 CARE AT THE VASCULAR HUB

The 2018 Vascular Society Provision of Vascular Services (POVS) did not include ALI in its time critical conditions or in amputation avoidance.<sup>[2]</sup> There are around 5,000 to 6,000 major amputations annually in the UK and the focus has been on chronic limb-threatening ischaemia (CLTI) to reduce amputation rates. Opportunities to reduce amputations and improve overall care for those who develop ALI as a new condition or as consequence of CLTI, have been overlooked until now.

The 2021 POVS included ALI,<sup>[32]</sup> and recommends that vascular networks have a written clinical pathway for its management, that ambulances should bypass local emergency departments (spoke hospitals) to avoid delays in presenting to the vascular hub. However, ALI was not included in the time critical conditions in the updated 2024 POVS.<sup>[33]</sup>

There were 192/330 (58.2%) patients who presented directly to a vascular hub. The most common route was via presentation to an emergency department (82/192; 42.7%), followed by primary care referrals (30/192; 15.6%) and blue light ambulance (34/192; 17.7%) (T8.1).

Table 8.1 Mode of presentation to the vascular hub	Number of patients	%
Transfer from a spoke hospital	138	41.8
Emergency department (within the vascular hub)	82	24.8
Ambulance attendance, blue light to the emergency department	34	10.3
Referral from a GP/primary care transfer	30	9.1
Referral from another inpatient unit	17	5.2
Other ambulance attendance	10	3.0
Referral from another clinic	9	2.7
Referral from a vascular surgery clinic	8	2.4
Referral from NHS 111	2	<1
<b>Total</b>	<b>330</b>	

*Case review data*

### Time to surgery

Patients diagnosed and transferred from a spoke hospital were referred directly to vascular surgery. This was supported by their median time from arrival at the vascular hub to procedure of 15.4 hours (F8.2). The median time from presentation at the vascular hub to procedure was 28.4 hours. Attendances at the vascular hub were a more varied group of patients, with some attending the emergency department at a vascular hub because it was their local hospital and some who called an ambulance and required triage and assessment before referral to vascular surgery.




Figure 8.1 Time from arrival in vascular hub to time of procedure - patients admitted directly to vascular hub and those transferred from spoke hospital

Case review data

When ALI is diagnosed in primary care or when the patient is known to be under the care of vascular surgery for chronic ischaemia, there are opportunities to accelerate the care by referring directly to vascular surgery if the network links primary care with the hospitals.

The '6Ps' were inconsistently recorded at the first assessment in the vascular hub (T8.2). Limb pulses (276/293; 94.2%) and pain (253/293; 86.3%) were most recorded. Paraesthesia was recorded in 177/293 (60.4%) patients. Paraesthesia affecting the toes only is categorised as Rutherford IIa ALI, i.e. it is not an indicator of an immediately threatened limb. As noted in the primary care section, it is not uncommon for an ALI limb to be swollen. Limb swelling was present in 27/293 (9.2%) patients. This may cause some diagnostic confusion with deep vein thrombosis and cellulitis if it is not recognised as being present in some patients with ALI.

Table 8.2 Symptoms recorded in the vascular hub	Number of patients	%
Limb pulses	276	94.2
Pain	253	86.3
Cold limb	204	69.6
Paraesthesia	177	60.4
Pallor	146	49.8
Paralysis/weakness	110	37.5
Swollen limb	27	9.2

Answers may be multiple; n=293

Clinician questionnaire data

A Rutherford category was documented in the vascular hub for 69/330 (20.9%) patients (T8.3). When a Rutherford category was not recorded, reviewers estimated the category based on the patient history and examination in the hospital notes.

Table 8.3 Rutherford category	Recorded on admission in the vascular hub notes	Estimated by reviewers	Combination of recorded/estimated
Rutherford I	16 (23.2%)	52 (22.4%)	68 (22.6%)
Rutherford IIa	24 (34.8%)	100 (43.1%)	124 (41.2%)
Rutherford IIb	21 (30.4%)	56 (24.1%)	64 (21.2%)
Rutherford III	8 (11.6%)	24 (10.3%)	32 (10.6%)
<b>Subtotal</b>	<b>69</b>	<b>232</b>	<b>301</b>
Unable to calculate	261	98	29
<b>Total</b>	<b>330</b>	<b>330</b>	<b>330</b>

Case review data

In 81/105 (77.1%) sets of case notes, reviewers stated that there was no change the patient's limb condition between presentation to the spoke hospital and transfer to the vascular hub. Nine patients' limbs improved from Rutherford IIa to I with three on anticoagulation alone. In 15 patients there was a deterioration in their limb with 8/15 deteriorating to a Rutherford category IIb, an immediately threatened limb that required urgent revascularisation for salvage, and 3/15 to an unsalvageable limb requiring amputation (T8.4 and T8.5).

Table 8.4 The Rutherford category changed between the spoke hospital and the vascular hub	Number of patients	%
Stayed the same	81	77.1
Deteriorated	15	14.3
Improved	9	8.6
<b>Subtotal</b>	<b>105</b>	
Unknown	33	
<b>Total</b>	<b>138</b>	

Case review data

Table 8.5 Detail of the deterioration in Rutherford category	Number of patients
Rutherford I to Rutherford IIb	4
Rutherford IIa to Rutherford IIb	8
Rutherford IIb to Rutherford III	3
<b>Total</b>	<b>15</b>

Case review data

Despite the limitations in the documentation of clinical findings, the reviewers considered the initial assessment satisfactory in 290/330 (87.9%) patients and all necessary investigations performed in 307/330 (93.0%).

There was a delay in making the diagnosis of ALI in the vascular hub in 25/297 (8.4%) patients, including 18/25 emergency department attendances (T8.6). This reinforces the need for effective

emergency department initial assessment of acutely painful limbs to correctly diagnose and accelerate the care of those with ALI. The most common reasons for the delay were misdiagnosis in 12 patients, deep vein thrombosis in six and chronic limb-threatening ischaemia in six (T8.7).

<b>Table 8.6 Delay in the diagnosis of ALI in the vascular hub</b>	<b>Number of patients</b>	<b>%</b>
Yes	25	8.4
No	272	91.6
<b>Subtotal</b>	<b>297</b>	
Unknown	9	
N/A - diagnosis already made in spoke hospital	24	
<b>Total</b>	<b>330</b>	

*Case review data*

<b>Table 8.7 Reasons for the delayed diagnosis in the vascular hub</b>	<b>Number of patients</b>
Misdiagnosed as deep vein thrombosis	6
Misdiagnosed as chronic limb-threatening ischaemia	6
Diagnosis missed	3
Delay in imaging	3
Referred to the stroke team	2
No details provided	5
<b>Total</b>	<b>25</b>

*Case review data*

Once ALI was diagnosed, or at least considered, a timely review by a vascular surgeon of sufficient seniority to plan their care occurred in 270/330 (81.8%) patients. Using an ALI pathway in the vascular hub appeared to have a positive impact on care: 3/46 (6.5%) patients experienced a delay on an ALI pathway compared to 18/165 (10.9%) not on a pathway.

This view of care was not supported by the emergency and acute care physicians in the clinician survey, who reported that delays were frequently attributed to vascular surgical refusal to see patients before imaging had been performed and a failure to advocate for imaging acceleration.

The clinician survey supported the use of an ALI pathway across spoke hospitals and vascular hubs, which included decision-making tools, reliable lines of communication with vascular surgery and advice on imaging and its urgency. Of the emergency and acute medicine respondents who worked in a vascular hub, 4/11 reported having such a document, which dropped to 3/21 in spoke hospitals.

ALI care pathways should include a preferred imaging modality (CT, MRI or ultrasound, depending on local access/clinical preference) and a process to prioritise an agreed multidisciplinary treatment plan. A delay in treatment planning occurred in 34/330 (10.3%) patients (T8.8). Current NICE guidance states that patients should be assessed for risk factors for iodinated contrast-induced acute kidney injury but that this should not delay emergency CT scans.<sup>[34]</sup>

<b>Table 8.8 Reasons for delay in treatment planning</b>	<b>Number of patients</b>
Awaiting imaging	11
Awaiting multidisciplinary input	8
Reviewers unable to determine a reason from the records	8
Awaiting senior surgical review	6
Awaiting anticoagulation	1
<b>Total</b>	<b>34</b>

*Case review data*

## **Training**

This study found delays in the triage, assessment, and diagnosis of patients with ALI in all clinical settings, including vascular hubs. Survey responses indicated that 21/41 vascular hubs provided work-based training in the recognition and management of ALI. In the majority this was focused on vascular surgical residents, with 6/21 extending it to the emergency department and/or foundation/core surgical residents. We did not ask about education on ALI provided in spoke hospitals or primary care. There are opportunities to improve ALI care with better and broader education and improved triage/initial assessment tools.



## 9 PROCEDURES UNDERTAKEN

There were 249/330 (75.5%) patients in this study who underwent one or more procedure with 78/330 (23.6%) treated with an anticoagulant alone or with palliative care.

Overall, in the 249 patients who had a procedure, the median time to treatment was four days (F4.9). These included 35/249 (14.1%) patients who had a primary amputation, where delaying surgery to optimise the patient or define the required level of amputation can reflect good practice.

Rutherford category IIb patients require revascularisation unless palliative care is more appropriate. Delays from symptom onset to anticoagulant administration and/or the first procedure may contribute to poorer outcomes. The identification of significant sensory and/or motor compromise and absent arterial Doppler signals (Rutherford category IIb) should trigger immediate revascularisation. This limb- and potentially life-saving procedure should be prioritised over all except lifesaving operations, particularly since such cases represent only a quarter of ALI admissions.

Of the 52 patients classified as having Rutherford category IIb ALI, only 5/52 (9.6%) achieved the six-hour target, with a median time of 3.1 days (F9.1). Delays to revascularisation in Rutherford category IIb ALI not only puts the limb at additional risk, but may result in additional interventions such as fasciotomies, that could have been avoided with earlier treatment. Of those who had a procedure more than six hours from the onset of symptoms, 17 patients had an amputation and eight had fasciotomies. Prompt treatment is indicated in patients with Rutherford category IIb ALI; the median time to treatment for the whole population was ten days.




Figure 9.1 Time from onset of symptoms to procedure

*Case review data*

There were three patients with Rutherford category III ALI who had a revascularisation procedure. The lines between the Rutherford categories may not be distinct in an individual and intra-operative assessment of limb viability can be indicated in some patients.

## First procedure

There is known variation in how doctors treat ALI, often based on their experience and available resources rather than strong clinical evidence.<sup>[35]</sup> Open surgical revascularisation was more commonly performed (159/249; 63.9%) than endovascular (28/249; 11.2%) as the primary revascularisation procedure (T9.1). Whether this was influenced by clinical preference or theatre/interventional radiology capacity is not known. However, it appears likely that interventional radiology availability played a role, as 51/52 (98.1%) vascular hubs had a 24/7 consultant vascular surgeon rota, while only 38/52 (73.1%) had a 24/7 interventional radiology rota. Data collection in a future national ALI registry would inform service planning (including staffing) and optimal revascularisation strategies. Primary amputations were performed in 35/249 (14.1%) patients and 20/249 (8.0%) required fasciotomies.

Table 9.1 First procedure performed	Number of patients	%
Surgical revascularisation procedure	159	63.9
Amputation	35	14.1
Fasciotomy	34	13.6
Endovascular revascularisation procedure	28	11.2
Hybrid revascularisation procedure/surgical and endovascular	22	8.8

Answers may be multiple,  $n=249$

*Case review data*

Hybrid operations require two teams or high-level dual competency (combined open and endovascular). These were less commonly performed (22/249; 8.8%). Simpler hybrid procedures can be performed in an interventional radiology theatre with theatre-quality air exchanges, but complex hybrid procedures require a hybrid theatre.<sup>[36]</sup> It is recommended that vascular hubs have at least one hybrid theatre to allow combined open and endovascular treatment.<sup>[2]</sup> In the organisational questionnaire 18/48 vascular hubs reported that they did not have any hybrid theatres.

Among patients categorised as having Rutherford IIb ALI, open surgery was the more common approach (45/69). Of these, eight patients underwent fasciotomies and 11 required amputations. A further seven patients had an endovascular procedure and six had a hybrid procedure.

Delays to revascularisation or amputation were observed in 50/249 (20.1%) patients, including 11 with Rutherford category IIb ALI. The delay was considered to have altered the outcome in three patients. The reason for the delay was not recorded in 17/50 patients and not all the delays were within the control of the clinicians or the hospital (F9.2). In 7/50 instances it was the patient's decision, while eight patients required medical stabilisation before proceeding. National data would provide greater oversight of the delays impacting on patient outcome.




Figure 9.2 Reasons for delays in procedure being performed;  $n=50$

Case review data

A patient with sensory-motor deficit (Rutherford category IIb) has an immediate threat to limb and life. Prioritisation should be based on the duration of the sensory-motor impairment rather than the time of theatre booking. If symptoms have already persisted beyond four hours, it is important to treat the patient more urgently – by placing them at the top of an emergency (CEPOD) list, opening a second emergency theatre or interrupting an elective list, whichever is the quickest. Theatre booking systems and emergency theatre co-ordination are processes designed to facilitate appropriate prioritisations. When conflicts arise, these must be resolved quickly, with senior clinical decision-makers taking responsibility. Generally, life- or limb-saving surgery should proceed even if the patient is not fasted.

Patients with Rutherford category IIa ALI should be treated as soon as reasonably possible and within 24 hours of theatre booking to avoid deterioration. However, individualised prioritisation is indicated, e.g. a patient who cannot be safely anticoagulated should receive earlier intervention.

Postoperatively, ward care was considered appropriate for 232/237 (97.9%) patients. A record of the limb condition postoperatively was found in 172/190 (90.5%) sets of notes and the limb had improved in 134/159 (84.3%) patients (19 amputations excluded).

The reviewers highlighted several areas of good quality care postoperatively including appropriate analgesia in 215/220 (97.7%) patients and appropriate anticoagulation in 228/233 (97.8%).

Complications occurred in 69/243 (28.4%) patients, of which three were considered avoidable and affected the patient's outcome.

Despite complications being managed appropriately in 64/69 patients, they affected the outcome of 25 patients, including two deaths. In 7/25 patients there were ALI specific complications and non-specific complications including cerebrovascular events (4) and respiratory complications (4).

There was room for improvement in the postoperative monitoring/escalation plans with a complete plan documented in the notes for only 82/249 (32.9%) patients (T9.2). No monitoring/escalation plan

was documented for 57/249 (22.9%) patients and 108/249 (43.4%) had key components for safe postoperative care missing.

Patients who were on an ALI pathway/proforma were more likely to have a complete monitoring plan (23/39; 59.0%) than those not managed on an ALI pathway/proforma (43/159; 27.0%). While this may reflect the positive impact of an ALI pathway/proforma, it may also be that units that have developed a pathway/proforma are better organised.

Table 9.2 An appropriate monitoring/escalation plan for deterioration was documented	Number of patients	%
Yes, a complete plan documenting frequency of monitoring	82	32.9
Yes, but an incomplete plan	53	21.3
Monitoring plan without escalation protocols	45	18.1
Escalation plan but no monitoring plan	10	4.0
No plan documented in notes	57	22.9
<b>Total</b>	<b>249</b>	

*Case review data*

### Additional procedures

In 57/233 (24.5%) patients, one or more subsequent procedure(s) were performed (11 patients had more than two). Surgery was the most common approach for second procedures (29/57) (T9.3).

Table 9.3 Overall number of procedures performed	Number of patients	%
1	176	75.5
2	46	19.7
3	8	3.4
4	3	1.3
<b>Total</b>	<b>233</b>	

*Clinician questionnaire data*

Amputations were included in 22/57 of second procedures (seven below-knee and 12 above-knee amputations). Fasciotomies were performed in fewer than five second procedures, reflecting their time-critical nature and the limited benefit of performing them after eight hours, unless there is a deterioration in the limb indicating the need for a fasciotomy. Haematoma/wound collection drainage were the reason for 5/57 second procedures.

Endovascular revascularisation treatments comprised a greater proportion of second procedures (13/57; 22.8%) than the primary procedure (37/233; 15.9%). The second-stage surgical revascularisations included 19 thromboembolectomies with 12/19 requiring a bypass graft.

Although endovascular (IR) mechanical thrombo-aspiration/thrombectomy is widely discussed and promoted, it was rarely utilised in this snapshot of practice in 2023. It was included in nine primary procedures. While recent publications have reported encouraging findings<sup>[37,38]</sup> there is no outcome data comparing it with open surgical revascularisation, and the devices (excluding those for stroke) are not currently reimbursed through the Specialised Services Devices Programme,<sup>[39]</sup> so the

financial cost for these expensive systems for ALI will likely delay their adoption into day-to-day UK practice.

The second procedure was inappropriately delayed in 8/57 patients due to theatre availability, patient decision, and delayed recognition of recurrence of ALI. Three or more procedures were uncommon (14) and when they did occur, they most commonly included an amputation (10/14) (F9.4).

There were some indicators that the care provided after the second procedure was less good than after the first procedure. The limb condition was not assessed in 9/65 patients postoperatively and analgesia and anticoagulation were inappropriate in others.




Figure 9.4 Procedures performed  
 Answers may be multiple; n=230  
 Clinician questionnaire data

Where an assessment could be made, communication with the patient and/or their family was considered to be good (185/204; 90.7%), but in 19/204 (9.3%) it could have been improved. In a larger number (126/330; 38.2%), the reviewers could not make an assessment, indicating that the documentation of communication needs to be improved.

# 10 DISCHARGE AND OUTCOME

[\(BACK TO CONTENTS\)](#)

The median length of stay was 19 days for the whole study population and 28 days for patients who had an amputation (F5.1). Patients who have an amputation typically require longer admissions. The mean number of dedicated vascular surgery beds in vascular hubs was 26.4 (range 15-60) with two stating that they had no dedicated beds. Vascular hubs must have the infrastructure and staffing necessary to support their commissioned services.




Figure 10.1 Length of stay in hospital for the study population;  $n=285$  and for patients who had an amputation;  $n=29$

Case review data

Where possible and appropriate, networks can improve access to services by using other facilities when vascular hub care is no longer required. However, this process currently appears to be under-developed as only 10/291 (3.4%) patients who survived were discharged back to a spoke hospital and 13/291 (4.5%) were transferred to a step-down or rehabilitation unit.

The 'Provision of Vascular Services 2018' describes repatriation 'rules' as "*making or breaking the capacity of an arterial centre to deliver good, timely care ....this needs to be at executive level because of the implications it has on the wider functioning of all hospitals concerned.*"<sup>[2]</sup> Only 18/58 vascular hubs returning an organisational questionnaire stated that they had a policy or standard operating procedure for repatriating patients to their referring hospital. Care closer to a patient's home also makes it easier for friends and relatives to visit, assisting recovery.<sup>[40]</sup>

## Discharge planning

NCEPOD reports frequently identify issues with the quality of discharge summaries which results in incomplete communication between hospital services and primary care, affecting continuity of care and safety-netting.

The reviewers identified a discharge summary for 262/291 (90.0%) patients who survived to discharge. Information was missing in 44/262 (16.8%), and the discharge planning was considered inadequate in 19/257 (7.4%) (T10.1). The most common omission was details of the vascular follow-up (27/44; 61.4%). Referrals to community services, including diabetic clinics, were missing in 26/44 (59.1%). The diagnosis was not recorded in 23/44 (52.3%) patients. Of note was the fact that just 6/61 (9.8%) patients who had recently undergone an amputation were referred for psychological support. ALI-specific discharge proformas may help to improve oversight of the discharge process and communication.

Table 10.1 Information missing from the discharge summaries	Number of patients	%
Details of a follow-up appointment with the vascular surgeon	27	61.4
Referrals to community services	26	59.1
Diagnosis	23	52.3
Referral for psychological support	6	13.6
Risk of return of symptoms	5	11.4
Telephone number to call if the patient has problems	4	9.1
Medications prescribed at discharge	4	9.1
Care plan	4	9.1
Details of the procedure/s performed	3	6.8
Wound care advice	2	4.5
Case worker's details	1	2.3

*Answers may be multiple; n=44*

*Case review data*

Currently, there is no standardised risk management package for people with ALI. Risk management is individualised based on the cause of ALI and patient risk factors.<sup>[28]</sup>

Anticoagulants were prescribed in 148/291 (50.9%) patients and antiplatelet medication in 114/291 (39.2%) (F10.2). Any medications not documented on a discharge plan with a specified duration of prescription may be discontinued at the first primary care review. Although published studies show that 25% of patients with ALI have evidence of thrombophilia, there is no consensus on what, if any, therapy is indicated after an ALI.<sup>[28]</sup>




Figure 10.2 Long-term risk management/advice at discharge *Answers may be multiple; n=291*  
Case review data

In the broader population of people with peripheral arterial disease (PAD), there is good evidence that low-dose rivaroxaban (2.5 mg twice a day) plus low-dose aspirin once a day improves outcomes compared to aspirin alone. In the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial this combination reduced major adverse limb events (including ALI and major amputation) by 46% and major adverse cardiovascular events by 28%, with no increase in severe bleeding.<sup>[25]</sup>

In total, 166/330 (50.3%) patients in this study had a revascularisation procedure and were discharged with an intact limb. For patients in the VOYAGER PAD trial who had undergone revascularisation, the combined medications significantly lowered the composite incidence of ALI, major amputation, myocardial infarction, ischaemic stroke, or death. However, the effects on major bleeding were mixed, with one measure showing no increase and another showing a significant increase compared to aspirin alone.<sup>[24]</sup>

Only 23/291 (7.9%) patients were documented as being commenced on the 'COMPASS/VOYAGER PAD regimen', with a possible additional 55/291 (18.9%) patients (those taking a DOAC and antiplatelet medication) being prescribed it without naming it. It is unknown if alternative focused strategies may be more effective in specific causes of ALI or patient subgroups. The role of antiplatelets, the various available anticoagulants or a combination of the two requires evaluation across the various causes of ALI. Future national guidance should include a consensus and data-based best practice post-ALI pharmacological regimen until data specific to ALI become available.

Of the 76 patients with known diabetes prior to their ALI, 70/76 (92.1%) had type 2 and 6/76 (7.9%) had type 1. In 43/76 (56.6%) a need for improved diabetes management was identified.



A follow-up appointment was not arranged for 45/291 (15.5%) patients. The reviewers considered that this was inappropriate for 16/45 patients.

No risk management was documented for 44/291 (15.1%) patients and where documentation existed, it was considered inadequate in 20/291 (6.9%) cases, including 15 patients who should have had smoking/vaping cessation advice. Smoking cessation advice was offered to 58/92 (63.0%) current smokers.

### Support and functional status

ALI is a life changing event for many patients. For those who survived, 210/330 (63.6%) patients were discharged home without the need for additional support, whereas at admission this figure was 162/330 (49.1%) (F10.3).




Figure 10.3 Discharge destination of the study population;  $n=330$

Case review data

While the Rockwood frailty score for 141/255 (55.3%) patients was unchanged at discharge, a small number showed an improvement (18/255; 7.1%), and the reviewers identified a deterioration in functional status in 68/255 (26.7%) patients (T10.2).

Table 10.2 Change in Rockwood frailty score between admission and discharge	Number of patients	%
No change	141	55.3
Decrease in functionality	68	26.7
The patient died	28	11.0
Increase in functionality	18	7.1
<b>Subtotal</b>	<b>255</b>	
Unable to answer	38	
<b>Total</b>	<b>293</b>	

Case review data

## **Readmission**

Readmissions within 30 days were uncommon (16/291; 5.5%); 7/16 were for issues with the same limb including infection and/or worsening ischaemia requiring another procedure.

## **Mortality**

The 30-day mortality for this group of patients was 12.7% (42/330), of which the inpatient mortality for patients admitted to a vascular hub was 11.8% (39/330) patients. This included 13 patients who had a revascularisation procedure, nine amputations and 17 who did not undergo a procedure in the vascular hub. The mortality for those who underwent surgery was 6.7% (22/330).

Of the inpatient deaths, 26/39 were considered predictable with all receiving palliative care at some point in their care pathway. There were 16/39 patients who had a medical certificate of cause of death, and ALL was listed in part 1a for seven of these patients.

## 11 OVERALL QUALITY OF CARE




Figure 11.1 Overall quality of care;  $n=320$

Case review data

The reviewers were asked to assign a grade to the overall quality of care received by each patient in the study (F11.1). Overall quality of care was rated as good for 169/320 (52.8%) patients. The reviewers reported there was room for improvement in the clinical and/or organisation of care for 151/320 (47.2%). A less than satisfactory rating was assigned to four patients (1.3%). These ratings do not consider the patient factors that have been shown to impact the care in this study.

Measuring performance is crucial for quality improvement. Only 22/47 vascular hubs stated that they recorded data on surgical procedures, while 19/42 collected data on interventional radiological revascularisation procedures for ALI. When asked about shared learning across the ALI network, the use of prospectively collected data was uncommon with most learning occurring in morbidity and mortality meetings or in response to reported adverse events.

Delays were identified as a key area of concern in improving ALI care. Considering the data relating to delays in the pathway, 123/249 (49.4%) individual patients who had a procedure experienced a delay at some stage between their initial presentation and first procedure. Excluding the patient-related delays in presenting, there were 115/249 (46.2%) individual patients delayed at some point in the pathway. National data collection for ALI would aid benchmarking and monitoring of the delays occurring throughout the entire ALI pathway. This could focus resources as well as educational opportunities.

The vascular hubs identified delays in patient presentation, initial assessment, recognition of and imaging for ALI as areas requiring improvement, along with transfer delays between vascular hubs and spoke hospitals. Additional challenges included a limited number of vascular surgical beds, the lack of a hybrid theatre, and too few interventional radiologists, limiting the treatment options. Embedding this into a registry would ensure that these factors can be considered beyond this report alone.